Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact

被引：0
|
作者：
Diaz-Guardamino, I. Echavarria [1 ]
Lopez-Tarruella Cobo, S. [2 ]
Del Monte-Millan, M. [2 ]
Alvarez, E. [2 ]
Jerez Gilarranz, Y. [2 ]
Moreno Anton, F. [3 ]
Garcia Saenz, J. A. [4 ]
Massarrah, T. [1 ]
Ocana, I. [5 ]
Cebollero, M. [6 ]
Ballesteros Garcia, A. I. [7 ]
Bohn Sarmiento, U. [8 ]
Gomez, H. [9 ]
Fuentes Rivera, H. [10 ]
Herrero Lopez, B. [11 ]
Polo, C. [12 ]
Bueno, O. [13 ]
Rahimi, P. [5 ]
Bueno Muino, C. [14 ]
Martin Jimenez, M. [15 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Inst Invest Sanitaria Gregorio Maranon, CiberOnc, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, CIBERONC ISCIII, GEICAM,Spanish Breast Canc Grp, Madrid, Spain
[3] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain
[4] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, CIBERONC, Med Oncol Dept, Madrid, Spain
[5] Inst Invest Sanitaria GregorioMaranon, Dept Med Oncol, Madrid, Spain
[6] Hosp Gen Univ Gregorio Maranon, Pathol, Madrid, Spain
[7] Hosp Univ Princesa, Dept Med Oncol, Madrid, Spain
[8] Hosp Univ Gran Canaria Doctor Negrin, Dept Med Oncol, Las Palmas Gran Canaria, Canary Island, Spain
[9] Oncosalud SAC, Radioncol Dept, Lima, Peru
[10] Aliada Canc, Ctr Oncol, Dept Med Oncol, Lima, Peru
[11] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain
[12] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain
[13] Hosp Gen Univ Gregorio Maranon, Radiol, Madrid, Spain
[14] Hosp Sur, Med Oncol, Madrid, Spain
[15] Hosp Gen Univ Gregorio Maranon, Med Dept, Serv Oncol, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
261P
引用
收藏
页码：S324 / S325
页数：2
相关论文
共 50 条
  • [11] Prognostic impact of histological subtyping in triple-negative breast cancer
    Grosse, Claudia
    Noack, Petar
    Grosse, Alexandra
    Preuss, Caroline Ines
    Schwarz, Heike Kathleen
    Gitter, Thomas
    Schrenk, Peter
    Frauchiger-Heuer, Heike
    Papassotiropoulos, Barbel
    Tausch, Christoph
    Maccio, Umberto
    Moch, Holger
    Langer, Rupert
    Varga, Zsuzsanna
    HUMAN PATHOLOGY, 2024, 152
  • [12] Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).
    Luen, Stephen James
    Salgado, Roberto
    Dieci, Maria Vittoria
    Vingiani, Andrea
    Curigliano, Giuseppe
    Hubbard, Rebekah
    Altamirano, Carlos Castaneda
    Sanchez, Joselyn
    D'Alfonso, Timothy
    Cheng, Esther
    Garcia, Miluska Castillo
    Adams, Sylvia
    Ahmed, Fahad
    Rimm, David L.
    Demaria, Sandra
    Symmans, William Fraser
    Michiels, Stefan
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [13] Subtyping of triple-negative breast cancer (TNBC): A cohort study
    Thomssen, Christoph
    Hartung, Caroline
    Porsch, Martin
    Stuckrath, Kathrin
    Buchmann, Jorg
    Kantelhardt, Eva J.
    Vetter, Martina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Pathologic and immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, S. M.
    Arnould, L.
    Briot, N.
    Desmoulins, I.
    Hennequin, A.
    Kaderbhai, C.
    Bertaut, A.
    Coutant, C.
    Causeret, S.
    Loustalot, C.
    Ilie, A.
    Derangere, V.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S432 - S432
  • [15] Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constatin, Guillaume
    Ilie, Alis
    Beltjens, Francoise
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Hennequin, Audrey
    Bertaut, Aurelie
    Coutant, Charles
    Causeret, Sylvain
    Ghozali, Niama
    Coudert, Bruno
    Arnould, Laurent
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [16] Impact of body mass index (BMI) on the predictive and prognostic value of stromal tumor-infiltrating lymphocytes (sTIL) in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NACT)
    Desmedt, Christine
    Richard, Francois
    Jongen, Lynn
    Hamy-Petit, Anne-Sophie
    Wildiers, Hans
    Ardui, Jan
    Punie, Kevin
    Smeets, Ann
    Berteloot, Patrick
    Vergote, Ignace
    Lae, Maricl
    Decroze, Diane
    Meseure, Didier
    Reyal, Fabien
    Biganzoli, Elia
    Neven, Patrick
    Floris, Giuseppe
    CANCER RESEARCH, 2020, 80 (04)
  • [17] Neoadjuvant treatments for triple-negative breast cancer (TNBC)
    von Minckwitz, G.
    Martin, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 39
  • [18] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)
    Krivorotko, P.
    Zhiltsova, E.
    Gigolaeva, L.
    Emelyanov, A.
    Pesotsky, R.
    Ereschenko, S.
    Levsghenko, V.
    Nikolaev, K.
    Komayachov, A.
    Ivanova, O.
    Tabagua, T.
    Zernov, K.
    Ivanov, V.
    Aseeva, Z.
    Bessonov, A.
    Semiglazov, V.
    BREAST, 2021, 56 : S52 - S52
  • [19] Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
    Lucci, A.
    Hall, C.
    Hess, K.
    Ravenberg, E.
    Clayborn, A.
    Mittendorf, E.
    Rauch, G.
    Candelaria, R.
    Moulder, S.
    Thompson, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [20] Real-world data (RWD) from patients with triple-negative breast cancer (TNBC) receiving pembrolizumab with neoadjuvant chemotherapy (NACT plus P) versus NACT alone
    Mckeon, J.
    Daniels, E.
    Gibbs, L.
    Comins, C.
    Jenkins, J.
    Strawson-Smith, T.
    Mohan, V.
    Allah, M. H.
    Braybrooke, J.
    Robinson, T.
    CLINICAL ONCOLOGY, 2025, 38
12345